Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information
Open Access
- 27 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (8), 1812-1823
- https://doi.org/10.1182/bloodadvances.2020001579
Abstract
In follicular lymphoma (FL), detection of bone marrow (BM) involvement (BMI) by F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) improves the accuracy of staging vs BM biopsy (BMB) alone. Our objective was to determine the diagnostic utility of PET for BMI FL and the prognostic value of BMI by PET (positive PET result [PET+]). Records of patients (2002-2016) with PET and BMB at the time of initial treatment were reviewed. BMI was identified by positive BMB result (BMB+) and/or unifocal or multifocal BM FDG uptake on blindly reviewed PET scans with no corresponding CT abnormality (PET+). Among 261 patients, BMI was diagnosed in 78 patients (29.9%) by PET+, in 81 patients (31.0%) by BMB+, and in 113 patients (43.3%) by either PET+ or BMB+. PET+ upstaged 24 patients to stage IV, including 10 from stages I or II to stage IV. Median duration of follow-up was 6.0 years (range, 0-16.6 years). In univariate analysis, a high Follicular Lymphoma International Prognosis Index (FLIPI) score, PET+, and BMB+ correlated with shorter progression-free survival (PFS; all P <= .03), and high FLIPI, PET+, and combined PET+ and BMB+ with shorter overall survival (OS; all P <= .01). In multivariate analysis, PET+ was the only independent predictor of PFS, whereas high FLIPI score and PET+ predicted OS (P <= .03). Combined PET and BMB identify BMI more accurately than either BMB or PET alone, but BMB rarely adds critical information. For patients initiating treatment of FL, identification of BMI by PET is predictive of PFS and OS.This publication has 30 references indexed in Scilit:
- Impact of age on clinical risk scores in follicular lymphomaBlood Advances, 2019
- Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative StudyJournal of Nuclear Medicine, 2017
- PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.Current Hematologic Malignancy Reports, 2016
- The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular LymphomaMedicine, 2016
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Combined PET and Biopsy Evidence of Marrow Involvement Improves Prognostic Prediction in Diffuse Large B-Cell LymphomaJournal of Nuclear Medicine, 2014
- The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphomaNuclear Medicine Communications, 2014
- Characterizing bone marrow involvement in Hodgkin’s lymphoma by FDG-PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor ProjectJournal of Clinical Oncology, 2009
- A Prognostic Score for Advanced Hodgkin's DiseaseThe New England Journal of Medicine, 1998